N O, a gaseous neuromodulator, plays an important role in the central nervous system control of blood pressure and heart rate. In the brain stem, NO is localized to several medullary nuclei involved in cardiorespiratory and gastrointestinal function. 1, 2 Neurons that contain the NO synthesizing enzyme, NO synthase (NOS), have been observed in many critical sites of central cardiovascular regulation, including the dorsal motor nucleus of the vagus, rostral ventrolateral medulla, caudal ventrolateral medulla, nucleus of the tractus solitarius (NTS), and the nucleus ambiguus (NA). 3 In the NA, NO is present in many of the terminal fields that surround cardiac vagal preganglionic neurons (CVPNs), including synaptic terminals from neurons that originate in the NTS. 4 CVPNs are primarily located within the external formation of the NA. [5] [6] [7] [8] [9] The CVPNs provide parasympathetic innervation to the heart and dominate control of the heart rate. CVPNs are intrinsically silent, and their activity is dominated by synaptic activation from other neurons that use neurotransmitters, such as acetylcholine, glutamate, GABA, and glycine, among others. 5,8 -12 NOS immunoreactivity is not directly colocalized with cholinergic neurons in the brain stem but rather is in small neurons, suggesting that NO is present in interneurons. 13, 14 This indicates that NO may exert its actions by modulating synaptic inputs to CVPNs. Microinjection of NO into the NA elicit decreases in heart rate, which are reversed by microinjections of N G -nitro-L-arginine methyl ester, an NOS inhibitor. 15 However, there is little known about the mechanisms by which NO alters parasympathetic cardioinhibitory activity in the brain stem. This study tests the hypotheses that NO modulates 3 critical synaptic inputs: glutamatergic, GABAergic, and glycinergic neurotransmission to CVPNs.
Methods

Slice Preparation
In an initial surgery, Sprague-Dawley rats (postnatal: days 2 to 6) were anesthetized with ketamine/xylazine and exposed to hypothermia during surgery (10 to 20 minutes) to slow the heart and aid in recovery. A right thoracotomy was used to expose the heart; rhodamine (XRITC, Molecular Probes, 2%, 20 to 40 L) was injected into the pericardial sac to retrogradely label CVPNs. Specificity of the cardiac vagal labeling is confirmed by the absence of any labeled neurons in the brain stem when rhodamine is injected into the chest cavity while keeping the pericardial sac intact or when the injection into the pericardial sac is accompanied by section of the cardiac branch of the vagus nerve (nϭ4). In other control experiments (nϭ10), intravenous injection of Յ10 mg of rhodamine failed to label any neurons in the medulla except for rare labeling of neurons in the area postrema, an area with a deficient blood-brain barrier. Although a recent report 16 suggests that there can be a lack of specificity using fluorescent tracers different from the one used in this study, Grkovic et al 16 injected tracers into the cardiac sac via an incision in the abdominal cavity and through the diaphragm, procedures that also greatly increase the probability of erroneous labeling.
On the day of the experiment (1 to 3 days after injection of the fluorescent tracer), the animals were anesthetized with halothane and euthanized by cervical dislocation. The brain was rapidly removed and placed in cold HEPES buffer (4°C) of the following composition (in mmol/L): NaCl (140), KCl (5), CaCl 2 (2), glucose (5), and HEPES (10), oxygenated with 100% O 2 . Slices of medulla 300 to 400 m in thickness were taken that included the NA. The slices were placed in a perfusion chamber and submerged in perfusate of the following composition (in mmol/L): NaCl (128), KCl (3), CaCl 2 (1.5), MgCl 2 (1), NaHCO 3 (24), NaH 2 PO 4 (0.5), and glucose (5), oxygenated with a 95%O 2 /5% CO 2 gas mixture. Previous work has shown that the O 2 tension within the tissue slice would be Ϸ600 mm Hg at the surface and 200 mm Hg at the core of the tissue under these conditions. 17 The osmolarity of both solutions was 285 to 290 mosmol, and the pH was maintained between 7.35 and 7.40. All of the animal procedures were performed in compliance with the institutional guidelines at George Washington University and were in accordance with the panel on euthanasia of the American Veterinary Medical Association and the National Institutes of Health publication Guide for the Care and Use of Laboratory Animals.
Electrophysiological Recording
Individual cardiac vagal neurons were identified by the presence of the fluorescent tracer 5 and imaged with differential contrast optics, infrared illumination, and infrared-sensitive video detection cameras to gain better spatial resolution and to visually guide and position the patch pipette onto the surface of the identified neuron. Pipettes were filled with a solution consisting of (in mmol/L): K gluconate (150), MgCl 2 (4), EGTA (2), Na-ATP (2), QX-314 (5), HEPES (10), with pH 7.3 for glutamate excitatory postsynaptic currents (EPSCs). For GABA and glycine postsynaptic inhibitory events (IPSCs), a pipette solution containing (in mmol/L): KCl (150), MgCl 2 (2), EGTA (2), Na-ATP (2), QX-314 (5), and HEPES (10) at pH 7.3 was used. Cardiac vagal neurons were studied using the whole-cell patchclamp technique and were voltage clamped at a holding potential of Ϫ80 mV.
To isolate glutamatergic currents, gabazine (25 mol/L), a GABA A receptor antagonist, and strychnine (1 mol/L), a glycinergic receptor antagonist, were added to the perfusate. Similarly, the non-NMDA and NMDA receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione ([CNQX] 50 mol/L) and D-2-Amino-5 phosphonovalerate ([AP5] 50 mol/L), respectively, as well as strychnine (1 mol/L), were added to the perfusate to isolate GABA IPSCs. Gabazine (25 mol/L), CNQX (50 mol/L), and AP5
(50 mol/L) were included in the perfusate to isolate glycine IPSCs. Tetrodotoxin ([TTX] 10 mol/L) was included in the perfusate to isolate miniature EPSCs (mEPSCs) and miniature IPSCs (mIPSCs). After the application of sodium nitroprusside (SNP) or L-arginine, the neurons were allowed to recover, and at the end of each experiment, spontaneous EPSCs were blocked by CNQX (50 mol/L) and AP5 (50 mol/L), respectively, whereas GABAergic and glycinergic IPSCs were blocked by gabazine (25 mol/L) and strychnine (1 mol/L), respectively. Analysis of spontaneous events was performed using MiniAnalysis (Synaptosoft, version 4.3.1). The minimal acceptable amplitude of synaptic events was set by determining the lowest threshold that elicited no events in the presence of the appropriate antagonist at the end of each experiment (AP5 and CNQX for glutamatergic, gabazine for GABAergic, and strychnine for glycinergic events, respectively). Typical thresholds were 8 to 15 pA. Results are presented as meanϮSEM, and data during control and drug applications were statistically compared with paired Student t test (for significant difference, PϽ0.05).
Results
Application of the NO donor SNP (100 mol/L) and NO precursor L-arginine (10 mmol/L) differentially affected excitatory and inhibitory neurotransmission to CVPNs. Both SNP and L-arginine significantly inhibited the frequency of glutamatergic EPSCs (SNP reduced glutamatergic EPSC frequency from 14Ϯ1.3 Hz to 6.7Ϯ1.3 Hz; PϽ0.05; nϭ9; L-arginine decreased EPSC frequency from 9.9Ϯ1.2 Hz to 6.3Ϯ1.1 Hz; PϽ0.05; nϭ11) but did not significantly alter EPSC amplitude. The results from a typical experiment and the summary data with application of SNP are shown in 33Ϯ5 pA to 27Ϯ3 pA; nϭ13), this reduction was not statistically significant.
In contrast, both SNP and L-arginine significantly inhibited glycinergic IPSC frequency. SNP decreased glycine IPSC frequency from 22Ϯ6 Hz to 10Ϯ4 Hz (PϽ0.05; nϭ8; Figure  3 , left), whereas L-arginine decreased glycine IPSC frequency from 47Ϯ7 Hz to 18Ϯ3 Hz (PϽ0.05; nϭ8; Figure 3 , right). In addition both SNP and L-arginine reduced glycinergic IPSC amplitude (SNP decreased amplitude from 54Ϯ8 pA to 44Ϯ5 pA; PϽ0.05; nϭ8; L-arginine significantly decreased amplitude from 115Ϯ18 pA to 72Ϯ13 pA; PϽ0.05; nϭ8).
To examine the specificity of L-arginine-evoked changes, L-arginine was applied in additional experiments in the presence of 7-nitroindazole ([7-NID] 100 mol/L), a selective neuronal NOS inhibitor. 18,19 7-NID had no significant effect on EPSC or IPSC frequency, amplitude, or holding current. In the presence of 7-NID, L-arginine had no significant effect on glutamatergic (left), GABAergic (middle), and glycinergic (right) neurotransmission to CVPNs (see Figure 4) .
To determine whether these changes in neurotransmission were action potential-dependent or could occur by altering presynaptic or postsynaptic function mEPSCs, GABAergic and glycinergic mIPSCs were isolated by inclusion of TTX (10 mol/L) in the perfusate. SNP significantly inhibited glutamatergic mEPSC frequency, whereas the amplitude of mEPSCs was not significantly affected (SNP decreased mEPSCs from 9.9Ϯ1.7 Hz to 6.5Ϯ1.6 Hz; PϽ0.05; nϭ9; see Figure 5 , left). In contrast, GABAergic mIPSCs were not significantly affected by application of SNP ( Figure 5 middle). SNP did significantly inhibit both glycinergic mIPSC frequency (from 24Ϯ3 Hz to 3Ϯ1 Hz; PϽ0.05; nϭ9) and amplitude (from 31Ϯ3 pA to 24Ϯ2 pA; PϽ0.05; nϭ9; see Figure 5 , right).
Discussion
Despite an extensive amount of literature on the role of NO in cardiac function, little is known about its role in central parasympathetic control of the heart. Although there is 
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considerable information demonstrating that NO has peripheral effects that alter cardiac function, 20 -22 other work in the literature indicate that NO also modulates the activity of central CVPNs in the brain stem. 15, 23, 24 Microinjections of NO into the NA decrease heart rate, a process that is reversed by N G -nitro-L-arginine methyl ester, a selective neuronal NOS (nNOS) inhibitor. 15 Furthermore, lack of nNOS activity decreases baseline parasympathetic tone and responses to vagal stimulation, because nNOS knockout mice have a higher heart rate and diminished cardiac reflex responses. 25, 26 This study provides a potential cellular basis for the NO-mediated alterations of parasympathetic cardiac activity. The NO donor SNP and the NO precursor L-arginine significantly decreased the frequency of glutamatergic neurotransmission to CVPNs but had no effect on EPSC amplitude. SNP also significantly decreased the frequency of glutamatergic mEPSCs but not mEPSC amplitude, suggesting that the effect of NO occurs at presynaptic glutamatergic synaptic terminals and not at postsynaptic sites. Both SNP and L-arginine increased the frequency of GABAergic neurotransmission to CVPNs but decreased the amplitude of GABAergic IPSCs. SNP did not alter the frequency or amplitude of GABAergic mIPSCs, indicating that the effects of NO on GABAergic neurotransmission to CVPNs are action potential dependent and likely occur by changing the firing characteristics of the GABAergic neurons that innervate CVPNs. Surprisingly, both L-arginine and SNP decreased the frequency and amplitude of glycinergic IPSCs. The decrease in frequency and amplitude persisted in glycinergic mIPSCs, indicating that the NO-mediated depression of glycinergic neurotransmission occurs at both the presynaptic glycinergic terminals, as well as possibly postsynaptic glycinergic receptors.
Consistent with the present data, in other brain regions, NO modulates release of neurotransmitters, including glutamate, GABA, and glycine. 27 NO has been shown to both increase and decrease glutamate release. 28 -30 In brain stem nuclei, such as the NTS, NO increases presynaptic release of glutamate in a positive feedback loop resulting from activation of Figure 4 . Application of L-arginine (10 mmol/L) had no effect on glutamatergic EPSCs (left) and GABAergic (middle) and glycinergic IPSCs (right) in identified CVPNs in the presence of 7-NID (100 mol/L), an nNOS inhibitor. Responses from a single neuron are shown on the left, whereas summary data from 8 (glutamatergic), 11 (GABAergic), and 8 (glycinergic) CVPNs are illustrated on the right in each panel. Figure 5 . The effects of SNP (100 mol/L) on glutamatergic mEPSCs (left) and GABAergic (middle) and glycinergic mIPSCs (right) were investigated in the presence of TTX (1 mol/L) in identified CVPNs. SNP significantly decreased glutamatergic mEPSC frequency but had no effect on mEPSC amplitude. Both GABAergic mIPSC frequency and amplitude were not significantly affected by SNP, whereas both glycinergic mIPSC frequency and amplitude were significantly decreased by SNP (100 mol/L). Responses from a single neuron are shown on the left and the summary data from 10 (glutamatergic), 13 (GABAergic), and 9 (glycinergic) CVPNs are illustrated on the right in each panel.
NMDA receptors. 31, 32 In DMVX neurons, NO enhances glutamatergic neurotransmission. 33 The present study reports that NO evoked a decrease in glutamate release to premotor CVPNs, demonstrating that the effect on the excitatory synaptic pathway to premotor CVPNs is very different from responses in the excitatory innervation of premotor gastrointestinal neurons in the dorsal motor nucleus of the vagus.
Other studies have shown that NO enhances GABAergic neurotransmission. Within the hypothalamus, NO acts at presynaptic sites to increase GABA release and, thus, inhibit the supraoptic oxytocin and vasopressin-releasing neurons. 34 -36 In agreement with the findings in this study, NO enhances GABAergic neurotransmission in the cerebellum via an action potential-dependent mechanism. 37 In the present study NO inhibited glycinergic neurotransmission to CVPNs by likely acting at both presynaptic and postsynaptic sites. This is one of the few studies to report the effects of NO on glycinergic neurotransmission. NO enhances glycinergic inhibition, 38, 39 as well as GABAergic inhibition, 39 in the spinal cord of Xenopus laevis tadpoles and in immature rat sympathetic preganglionic neurons. Differential responses to NO in GABAergic and glycinergic neurotransmission were reported in turtle retina slices where NO facilitated GABA and inhibited glycine release. 40 
Perspectives
The findings of the present study describe mechanisms by which NO directly modulates synaptic inputs to CVPNs. In particular, NO directly decreases glutamatergic and glycinergic neurotransmission while enhancing GABAergic neurotransmission. The inhibition of glutamatergic and glycinergic neurotransmission to CVPNs likely occurs at presynaptic terminals, as illustrated in Figure 6 , because the modulation of neurotransmission persists in the presence of TTX. In contrast, NO facilitates GABAergic activity in CVPNs, which is likely because of excitation of GABAergic neurons at their cell bodies, because this increased activity is action potential dependent (see Figure 6 ). The results reported here reveal that a complex balance exists in the NO modulation of brain stem parasympathetic control of the heart. It is possible that the NO inhibition of glycinergic neurotransmission dominates over changes in glutamatergic and GABAergic neurotransmission and is, therefore, responsible for the NOmediated increase in parasympathetic activity of the heart often observed in vivo. However, the results in this study strongly suggest that the actions of NO are very diverse and will not only be governed by the different modulation of these major synaptic inputs but also the dynamic activity of these different pathways to CVPNs.
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